Effects of Olmesartan on the Renin-angiotensin-aldosterone System for Patients with Essential Hypertension after Cardiac Surgery—Investigation Using a Candesartan Change-over Study—

DOI 被引用文献4件 参考文献31件
  • Sezai Akira
    Department of Cardiovascular Surgery, Nihon University School of Medicine, Tokyo, Japan
  • Soma Masayoshi
    Department of General medicine, Nihon University School of Medicine, Tokyo, Japan
  • Hata Mitsumasa
    Department of Cardiovascular Surgery, Nihon University School of Medicine, Tokyo, Japan
  • Yoshitake Isamu
    Department of Cardiovascular Surgery, Nihon University School of Medicine, Tokyo, Japan
  • Unosawa Satoshi
    Department of Cardiovascular Surgery, Nihon University School of Medicine, Tokyo, Japan
  • Wakui Shinji
    Department of Cardiovascular Surgery, Nihon University School of Medicine, Tokyo, Japan
  • Shiono Motomi
    Department of Cardiovascular Surgery, Nihon University School of Medicine, Tokyo, Japan

書誌事項

タイトル別名
  • Effects of Olmesartan on the Renin-angiotensin-aldosterone System for Patients with Essential Hypertension after Cardiac Surgery-Investigation Using a Candesartan Change-over Study-
  • Effects of olmesartan on the renin–angiotensin–aldosterone system for patients with essential hypertension after cardiac surgery—investigation using a candesartan change-over study

この論文をさがす

抄録

Background: Various angiotensin II receptor blockers are widely used for the treatment of hypertension in recent years. The results of large-scale clinical studies have shown that they have various efficacies: not only hypotensive effects but also organ protective effects. In this study, the effects of a change-over from candesartan to olmesartan on renin-angiotensin-aldsterone system, cardiomegaly and peripheral circulation were studied.<br>Methods: Participants enrolled in this trial were outpatients with essential hypertension after cardiac surgery who had received candesartan for more than one year. Fifty-six patients switched from candesartan to olmesartan. The primary endpoints were 1) renin activity, angiotensin II, aldosterone, and 2) left ventricular mass index (LVMI).<br>Results: It was clear that angiotensin II and aldosterone are decreased by the potent hypotensive effects of olmesartan in a change-over from candesartan to olmesartan. Since LVMI and BNP were decreased, inhibitory effects on myocardial hypertrophy were also confirmed.<br>Conclusion: In the present study, left ventricular hypertrophy and on arterial compliance were inhibited by a decrease in angiotensin II and aldosterone due to the change-over to olmesartan. In the future, protective effects on organs will be clarified by long-term observations.

収録刊行物

被引用文献 (4)*注記

もっと見る

参考文献 (31)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ